<DOC>
	<DOCNO>NCT02962414</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety patient TSC refractory seizure currently receive everolimus treatment Novartis-sponsored EXIST-3 study determine benefit continue treatment judge investigator completion EXIST-3</brief_summary>
	<brief_title>Roll-over Study Collect Assess Long-term Safety Everolimus Patients With TSC Refractory Seizures Who Have Completed EXIST-3 Study CRAD001M2304 Who Are Benefitting From Continued Treatment</brief_title>
	<detailed_description>This multi-center , open label study evaluate long term safety everolimus patient TSC refractory seizure currently treat Novartis-sponsored study EXIST-3 study judge parent study investigator benefit current study treatment . The study expect remain open approximately 10 year ( 31-Dec-2022 UK ) First Patient First Visit ( FPFV ) . Patients continue treat study longer benefit everolimus treatment judge Investigator one protocol define discontinuation criterion meet everolimus becomes commercially available accord local regulation .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Key Patient currently enrol Novartissponsored EXIST3 study , receive everolimus , fulfil requirement Patient currently benefit treatment everolimus , determine Investigator . Patient demonstrate compliance , assess Investigator , parent study protocol requirement . Patient willing able comply schedule visit treatment plan . Written inform consent/adolescent assent obtain prior enrol rollover study . Key Patient permanently discontinue everolimus study treatment EXIST3 study Everolimus approve patient TSC refractory seizure reimburse local country . Patients receive everolimus combination unapproved experimental treatment seizure control Antiepileptic drug ( AEDs ) allow purpose seizure control .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>Tuberous sclerosis complex</keyword>
	<keyword>TSC</keyword>
	<keyword>Refractory seizure</keyword>
	<keyword>Roll study</keyword>
	<keyword>Long term safety</keyword>
	<keyword>PASS</keyword>
</DOC>